Jacqueline Northcut, Interim CEO, is also serving as a Board Director of Chrysalis BioTherapeutics and as an Advisor to a venture fund in formation. She served as President and CEO of BioHouston from 2002 to 2015. During this same period, Ms. Northcut became the founder and CEO of Texas BioAlliance. In these capacities she and her team provided all facets of drug development strategy to Texas based companies and PIs. Companies that received their assistance subsequently raised more than a billion dollars. Ms. Northcut was previously a Partner in the international accounting firm of Arthur Andersen & Co., where she worked from 1984 to 2002 in various industries including biotechnology, medical device, venture capital and several service industries. She has extensive experience in mergers and acquisitions and public and private financings including scores of initial public offerings.
Darrell H. Carney, PhD, President and Chief Scientific Officer, is an Adjunct Professor in the Department of Biochemistry and Molecular Biology at the University of Texas Medical Branch and founder of Chrysalis BioTherapeutics, Inc. Among his most important academic research achievements were: the identification of thrombin receptors on fibroblasts, endothelial cells, and progenitor stem cells that initiate tissue regeneration; and discovery of peptide drugs that could selectively activate these receptors to stimulate regenerative processes and restoration of endothelial function. As an academic scientist, he raised over 13 million dollars in NIH funding and has over 90 publications and 28 patents. Dr. Carney established his first tissue repair company in 1995, and sold the company after completion of a Phase 2 clinical trial in 2004 and re-acquired the rights to the same technology in 2012.
Clarice Motter, Interim CFO, is a licensed CPA with more than 20 years’ experience as an accountant and administrative professional. Her experience in public and privately owned companies includes mergers, acquisitions, and public offerings. She has recently worked with a number of early-stage companies bringing them into fiscal compliance and playing a key role in raising funding through public and private sources.
Gerald M Fuller, PhD, Vice President of Technology, is a Professor Emeritus, Department of Cell Biology at the University of Alabama Medical School with expertise in molecular biology, progenitor cell biology, and the biology of vascular pericytes. Gerry was one of the first scientists to discover IL-6 and its involvement in stimulating hepatocytes. Gerry has been a scientific consultant with Chrysalis BioTechnology, OrthoLogic, and Merck and currently directs a team of scientists working to better understand the molecular mechanisms by which Chrysalin® targets progenitor cells to protect and regenerate tissues.
Laurie Sower, PhD, Vice President of Research, Director Regulated Laboratory Studies, has over 15 years in directing laboratory operations, quality data system management, and prior experience with Chrysalin®. Her prior research at the University of Texas Medical Branch demonstrated a unique TP508 (Chrysalin®) receptor-mediated signaling cascade involved in tissue repair. Laurie is the Principle Investigator (PI/PD) on the company’s SBIR Phase 2B grant and directs all Non-Clinical Regulated Studies for Chrysalis BioTherapeutics.
Jane Lea Hicks, Vice President of Product Development has over 30 years of experience in business and product development and was the former VP of Business Development for Life Cell Corporation. Ms. Hicks has a successful track record in commercializing technology products, generating a return for early-stage investors and mentoring start-up companies. Areas of specific expertise is in regenerative medicine and wound healing.